SHH and medulloblastoma: Dysregulation of Shh signaling has been involved with several malignancies, including basal cell carcinomas, medulloblastomas, leukemia, oral squamous cell carcinomas, and gastrointestinal, pancreas, lung, ovarian, breast, and prostate cancers [10–14].